GILD Stock Overview
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
Notes are coming soon
Gilead Sciences, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$79.20|
|52 Week High||US$79.20|
|52 Week Low||US$60.08|
|1 Month Change||0%|
|3 Month Change||25.12%|
|1 Year Change||9.97%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||18.03%|
Recent News & Updates
|GILD||PE Biotechs||PE Market|
Return vs Industry: GILD exceeded the PE Biotechs industry which returned 2.7% over the past year.
Return vs Market: GILD exceeded the PE Market which returned -8.5% over the past year.
|GILD Average Weekly Movement||7.1%|
|Biotechs Industry Average Movement||0%|
|Market Average Movement||0%|
|10% most volatile stocks in PE Market||0%|
|10% least volatile stocks in PE Market||0%|
Stable Share Price: GILD is more volatile than 75% of PE stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: GILD's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of PE stocks.
About the Company
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients.
Gilead Sciences, Inc. Fundamentals Summary
|GILD fundamental statistics|
Is GILD overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|GILD income statement (TTM)|
|Cost of Revenue||US$5.64b|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
Feb 02, 2023
|Earnings per share (EPS)||2.66|
|Net Profit Margin||12.29%|
How did GILD perform over the long term?See historical performance and comparison